Betaini's self-developed injectable sodium hyaluronate solution BTN001 has officially received approval from the National Medical Products Administration, obtaining a Class III medical device registration certificate with registration number 20263131919. This is the group's first self-developed Class III medical device approved for market. Institutional research reports note that Betaini, leveraging its Winona sensitive-skin base and Acoman clinical channel, uses BTN001 to close the loop of pre-operative stabilization, intra-operative injection, and post-operative repair, strengthening its full-cycle medical aesthetic service capability. The new product is restricted to medical institutions, with high barriers and large pricing space, and is expected to open a second growth curve. In terms of shareholder returns, as of August 31, 2026, the company had cumulatively repurchased 3.6997 million shares, accounting for 0.8734% of total share capital, with a total transaction amount of approximately 120 million yuan. At the same time, it launched its first interim dividend, proposing a cash dividend of 1.50 yuan per 10 shares to all shareholders, with an estimated total payout of approximately 62.639 million yuan. Controlling shareholder Guo Zhenyu also pledged in April this year not to reduce his holdings within 12 months. In the first half of 2026, Betaini achieved operating revenue of 2.592 billion yuan, up 9.27% year-on-year, net profit attributable to the parent of 292 million yuan, up 18.30% year-on-year, and non-GAAP net profit attributable to the parent of 246 million yuan, a sharp increase of 34.85% year-on-year. Net cash flow from operating activities was 394 million yuan, up 13.53% year-on-year. Gross margin reached 74.62%, and the selling expense ratio fell 3.64 percentage points year-on-year to 50.53%. However, Betaini's share price has fallen about 15% cumulatively this year, hovering around 30 to 35 yuan from late June to late September. As of September 30, it closed at 32.70 yuan per share, with a latest total market value of approximately 13.8 billion yuan.
Yunnan Botanee Bio-Technology Group Co LtdCompany launched its first interim dividend of 1.50 yuan per 10 shares and had cumulatively repurchased 3.6997 million shares for ~120 million yuan.
